{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T03:31:41Z","timestamp":1771039901368,"version":"3.50.1"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Digit. Health"],"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Digital applications have the potential to enhance diabetes management, particularly in patients treated with insulin. This study aims to evaluate the impact of a digital application on self-management (ESYSTA, Germany), expressed in a change in HbA1c levels, in people with diabetes treated with insulin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>A randomized controlled, multicentric trial was conducted in 204 people with diabetes (60% type 2 diabetes) treated with insulin to assess the efficacy of ESYSTA. Participants were randomly assigned to either the intervention group (IG) using ESYSTA in addition to the German standard of Care (SoC) according to the German disease management programs (DMP) for 6 months or a control group (CG) receiving SoC only. The primary endpoint was the change in HbA1c levels. Secondary endpoints included well-being and diabetes-related distress.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A clinically relevant reduction in HbA1c levels of on average \u22120.48% points (\u22120.66; \u22120.29) was observed in the IG after 6 months. Compared to the CG, this reduction was more pronounced, especially in the per-protocol sample [mean difference, \u22120.28% points; 95% CI (\u22120.54; \u22120.02)]. Improvements in the IG in further secondary endpoints, such as well-being or diabetes-related distress, indicate enhanced overall glycemic control and patient satisfaction in the IG.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The use of ESYSTA improved HbA1c levels and other secondary outcomes in people with diabetes who are treated with insulin in comparison with German SoC in the context of DMP. These findings support the integration of digital tools in routine diabetes care to optimize patient outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p><jats:ext-link>https:\/\/drks.de\/search\/de\/trial\/DRKS00025996<\/jats:ext-link>, identifier DRKS00025996.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fdgth.2025.1544668","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T11:33:02Z","timestamp":1751283182000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of a digital application on HbA1c levels in people with diabetes: a randomized controlled trial"],"prefix":"10.3389","volume":"7","author":[{"given":"Lena","family":"Roth","sequence":"first","affiliation":[]},{"given":"Nico","family":"Steckhan","sequence":"additional","affiliation":[]},{"given":"Peter E. H.","family":"Schwarz","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","year":"2010","journal-title":"Lancet"},{"key":"B2","article-title":"IDF Diabetes Atlas 2021 - 10 Edition. (2021)","year":""},{"key":"B3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"760778","DOI":"10.3389\/fendo.2022.760778","article-title":"Comorbidities in recent-onset adult type 1 diabetes: a comparison of German cohorts","volume":"13","author":"Zaharia","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B5","article-title":"Healthcare and health situation of adults with type 2 diabetes in Germany: The study GEDA 2021\/2022-Diabetes","author":"Heidemann","year":"2024"},{"key":"B6","volume-title":"Diabetes in Germany - National Diabetes Surveillance Report 2019","year":"2019"},{"key":"B7","article-title":"S3-Leitlinie Therapie des Typ-1-Diabetes. Version 2.0. AWMF-Register-Nr. 057-013. (2018)","year":""},{"key":"B8","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.2337\/dc23-S006","article-title":"6. Glycemic targets: standards of care in diabetes\u20142023","volume":"46","author":"ElSayed","year":"2022","journal-title":"Diabetes Care"},{"key":"B9","article-title":"Zentralinstitut f\u00fcr die kassen\u00e4rztliche Versorgung in der Bundesrepublik Deutschland. DMP-Atlas Nordrhein-Westfalen. Regionalisierte Darstellung der Disease-Management-Programme","year":"2024"},{"key":"B10","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.2337\/dc23-S007","article-title":"7. Diabetes technology: standards of care in diabetes\u20142023","volume":"46","author":"ElSayed","year":"2022","journal-title":"Diabetes Care"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/j.jacc.2018.07.081","article-title":"Blood sugar regulation as a key focus for cardiovascular health promotion and prevention: an umbrella review","volume":"72","author":"Schwarz","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B12","article-title":"The fast-track process for digital health applications (diga) according to section 139e sgb v a guide for manufacturers, service providers and users. version 1.0","year":"2020"},{"key":"B13","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1177\/19322968221075333","article-title":"Design of the DAVOS study: diabetes smartphone app, a fully automatic transmission of data from the blood glucose meter and insulin pens using wireless technology to enhance diabetes self-management\u2014a study protocol for a randomized controlled trial","volume":"17","author":"Grosser","year":"2023","journal-title":"J Diabetes Sci Technol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"754","DOI":"10.2337\/diacare.18.6.754","article-title":"Assessment of diabetes-related distress","volume":"18","author":"Polonsky","year":"1995","journal-title":"Diabetes Care"},{"key":"B15","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00125-005-0094-2","article-title":"How to screen for depression and emotional problems in patients with diabetes: comparison of screening characteristics of depression questionnaires, measurement of diabetes-specific emotional problems and standard clinical assessment","volume":"49","author":"Hermanns","year":"2006","journal-title":"Diabetologia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1026\/0012-1924.53.2.83","article-title":"Teststatistische Pr\u00fcfung und Normierung der deutschen versionen des EUROHIS-QOL Lebensqualit\u00e4t-index und des WHO-5 Wohlbefindens-Index","volume":"53","author":"Br\u00e4hler","year":"2007","journal-title":"Diagnostica"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1111\/dme.13779","article-title":"WHO-5 and BDI-II are acceptable screening instruments for depression in people with diabetes","volume":"35","author":"Rauwerda","year":"2018","journal-title":"Diabet Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12955-014-0185-1","article-title":"Assessing self-management in patients with diabetes mellitus type 2 in Germany: validation of a German version of the summary of diabetes self-care activities measure (SDSCA-G)","volume":"12","author":"Kamradt","year":"2014","journal-title":"Health Qual Life Outcomes"},{"key":"B19","doi-asserted-by":"publisher","first-page":"943","DOI":"10.2337\/diacare.23.7.943","article-title":"The summary of diabetes self-care activities measure: results from 7 studies and a revised scale","volume":"23","author":"Toobert","year":"2000","journal-title":"Diabetes Care"},{"key":"B20","article-title":"EQ-5D-5l User Guide (2019)","year":""},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.02.008","article-title":"Interim scoring for the EQ-5D-5l: mapping the EQ-5D-5l to EQ-5D-3l value sets","volume":"15","author":"van Hout","year":"2012","journal-title":"Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research"},{"key":"B22","volume-title":"R: A Language and Environment for Statistical Computing","year":"2024"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/nu14091810","article-title":"Impact of a digital lifestyle intervention on diabetes self-management: a pilot study","volume":"14","author":"Bretschneider","year":"2022","journal-title":"Nutrients"},{"key":"B24","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.3390\/jcm12196317","article-title":"Effectiveness of a digital health application for the treatment of diabetes type II\u2014a pilot study","volume":"12","author":"Bretschneider","year":"2023","journal-title":"JCM"},{"key":"B25","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.diabres.2018.09.002","article-title":"Integrated personalized diabetes management improves glycemic control in patients with insulin-treated type 2 diabetes: results of the PDM-ProValue study program","volume":"144","author":"Kulzer","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"B26","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1089\/dia.2017.0206","article-title":"Use of a novel, remotely connected diabetes management system is associated with increased treatment satisfaction, reduced diabetes distress, and improved glycemic control in individuals with insulin-treated diabetes: first results from the personal diabetes management study","volume":"19","author":"Mora","year":"2017","journal-title":"Diabetes Technol Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1177\/1932296815622646","article-title":"Remote health consultations supported by a diabetes management web application with a new glucose meter demonstrates improved glycemic control","volume":"10","author":"Grady","year":"2015","journal-title":"J Diabetes Sci Technol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"953-P","DOI":"10.2337\/db19-953-P","article-title":"953-P: sustainable improvement in quality of blood glucose control in users of mySugr\u2019s integrated diabetes management solution","volume":"68","author":"Mayer","year":"2019","journal-title":"Diabetes"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1007\/s00125-023-06006-2","article-title":"Clinical impact of an integrated e-health system for diabetes self-management support and shared decision making (POWER2DM): a randomised controlled trial","volume":"66","author":"Ruissen","year":"2023","journal-title":"Diabetologia"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1177\/19322968241239870","article-title":"Efficacy of a digital diabetes logbook for people with type 1, type 2, and gestational diabetes: results from a multicenter, open-label, parallel-group, randomized controlled trial","author":"Ehrmann","year":"2024","journal-title":"J Diabetes Sci Technol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.2196\/mhealth.3535","article-title":"A low-intensity Mobile health intervention with and without health counseling for persons with type 2 diabetes, part 1: baseline and short-term results from a randomized controlled trial in the Norwegian part of RENEWING HEALTH","volume":"2","author":"Torbj\u00f8rnsen","year":"2014","journal-title":"JMIR Mhealth Uhealth"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.2196\/mhealth.3882","article-title":"A Mobile health intervention for self-management and lifestyle change for persons with type 2 diabetes, part 2: one-year results from the Norwegian randomized controlled trial RENEWING HEALTH","volume":"2","author":"Holmen","year":"2014","journal-title":"JMIR Mhealth Uhealth"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e16791","DOI":"10.2196\/16791","article-title":"Mapping the evidence on the effectiveness of telemedicine interventions in diabetes, dyslipidemia, and hypertension: an Umbrella review of systematic reviews and meta-analyses","volume":"22","author":"Timpel","year":"2020","journal-title":"J Med Internet Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00508-019-1471-z","article-title":"Antihyperglyk\u00e4mische therapie bei diabetes mellitus typ 2 (update 2019)","volume":"131","author":"Clodi","year":"2019","journal-title":"Wien Klin Wochenschr"},{"key":"B35","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"Br Med J"},{"key":"B36","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) group","volume":"352","year":"1998","journal-title":"Lancet (London, England)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"995","DOI":"10.2337\/db07-1618","article-title":"Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial\u2014revisited","volume":"57","author":"Lachin","year":"2008","journal-title":"Diabetes"},{"key":"B38","article-title":"infas (Institut f\u00fcr angewandte Sozialwissenschaft GmbH). Bericht der strukturierten Behandlungsprogramme der gesetzlichen Krankenkassen \u2013 Indikation Diabetes mellitus Typ 1. Erstellt durch infas und MNC","author":"Huppmann","year":"2021"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.jval.2018.02.007","article-title":"Minimally important difference of the EQ-5D-5l Index score in adults with type 2 diabetes","volume":"21","author":"McClure","year":"2018","journal-title":"Value Health"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-056304","article-title":"Original research: how to identify clinically significant diabetes distress using the problem areas in diabetes (PAID) scale in adults with diabetes treated in primary or secondary care? Evidence for new cut points based on latent class analyses","volume":"12","author":"de Wit","year":"2022","journal-title":"BMJ Open"},{"key":"B41","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/(SICI)1520-7560(199905\/06)15:3%3C205::AID-DMRR29%3E3.0.CO;2-O","article-title":"Quality of life and diabetes","volume":"15","author":"Rubin","year":"1999","journal-title":"Diabetes Metab Res Rev"},{"key":"B42","doi-asserted-by":"publisher","first-page":"502","DOI":"10.4158\/EP.10.6.502","article-title":"Impact of improved glycemic control on quality of life in patients with diabetes","volume":"10","author":"Jacobson","year":"2004","journal-title":"Endocr Pract"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.2337\/diacare.22.7.1125","article-title":"Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective diabetes study group","volume":"22","year":"1999","journal-title":"Diabetes Care"},{"key":"B44","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1055\/a-2149-1840","article-title":"Digitale gesundheitsanwendungen in der Diabetologie: Ein \u00dcberblick","volume":"21","author":"Bretschneider","year":"2023","journal-title":"Diabetes Aktuell"},{"key":"B45","doi-asserted-by":"publisher","first-page":"984","DOI":"10.2337\/db23-984-P","article-title":"984-P: importance and use of smart insulin pens with connectivity for diabetes management","volume":"72","author":"Heinemann","year":"2023","journal-title":"Diabetes"},{"key":"B46","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1177\/1932296820965553","article-title":"Level of digitalization in Germany: results of the diabetes digitalization and technology (D.U.T) report 2020","volume":"16","author":"Roos","year":"2022","journal-title":"J Diabetes Sci Technol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1177\/1932296819867686","article-title":"Benefit of digital tools used for integrated personalized diabetes management: results from the PDM-ProValue study program","volume":"14","author":"Heinemann","year":"2019","journal-title":"J Diabetes Sci Technol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.zefq.2022.09.008","article-title":"Wie belastbar sind studien der aktuell dauerhaft aufgenommenen digitalen gesundheitsanwendungen (DiGA)? methodische qualit\u00e4t der studien zum nachweis positiver versorgungseffekte von DiGA","volume":"175","author":"Kolominsky-Rabas","year":"2022","journal-title":"Zeitschrift f\u00fcr Evidenz, Fortbildung und Qualit\u00e4t im Gesundheitswesen"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e44764","DOI":"10.2196\/44764","article-title":"Challenges with the use of digital sham: systematic review and recommendations","volume":"25","author":"Bos","year":"2023","journal-title":"J Med Internet Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.pcd.2023.03.006","article-title":"The power of the placebo effect in diabetes: a systematic review and meta-analysis","volume":"17","author":"Gossenheimer","year":"2023","journal-title":"Prim Care Diabetes"},{"key":"B51","article-title":"infas (Institut f\u00fcr angewandte Sozialwissenschaft GmbH). Bericht der strukturierten Behandlungsprogramme der gesetzlichen Krankenkassen \u2013 Indikation Diabetes mellitus Typ 2 Erstellt durch infas und MNC. Die gesetzlichen Krankenkassen","year":"2024"},{"key":"B52","doi-asserted-by":"publisher","first-page":"40","DOI":"10.9781\/ijimai.2017.445","article-title":"Construction of a benchmark for the user experience questionnaire (UEQ)","volume":"4","author":"Schrepp","year":"2017","journal-title":"IJIMAI"},{"key":"B53","volume-title":"User Experience Questionnaire Handbook. All You Need to Know to Apply the UEQ Successfully in Your Projects","author":"Schrepp","year":"2023"}],"container-title":["Frontiers in Digital Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdgth.2025.1544668\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T11:33:03Z","timestamp":1751283183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdgth.2025.1544668\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":53,"alternative-id":["10.3389\/fdgth.2025.1544668"],"URL":"https:\/\/doi.org\/10.3389\/fdgth.2025.1544668","relation":{},"ISSN":["2673-253X"],"issn-type":[{"value":"2673-253X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"article-number":"1544668"}}